Previous
Previous

Phosplatin Therapeutics Announces the Execution of Regional Licensing Agreement for its Novel Therapeutic Agent in Oncology, PT-112

Next
Next

Phosplatin Therapeutics Appoints José Jimeno, M.D., PhD as Chief Medical Officer